Skip to content
DataLookout
Menu

NCT05561751

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 19, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 37 words
    • Primary endpoint revised
    • Enrollment target: 30 to 28
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 2 words
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 40 to confirmed 30
    • Primary completion date changed from estimate of Aug 31, 2025 to Sep 30, 2025
    • Study completion date changed from estimate of Sep 30, 2025 to Oct 31, 2025
    v9
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Mar 29, 2025 to Aug 31, 2025
    • Study completion date: Jun 30, 2025 to Sep 30, 2025
    • Site details revised at 10 of 10 sites
    v8
  4. Notable Primary endpoint revisedv7
  5. Minor Site contacts updated at 3 of 10 sitesv6
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Primary completion date: Mar 29, 2024 to Mar 29, 2025
    • Study sites: 8 to 10
    • Study completion date: Jun 30, 2024 to Jun 30, 2025
    v5
  2. Minor Study sites: 1 to 8v4
  3. Minor Study description expanded, about 25 wordsv3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 114 words
    • Start date changed from estimate of Nov 30, 2022 to Feb 13, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis Sessions
Timeframe: First two leukapheresis sessions (study days 7 and 8)

Arms and interventions

GPC-100 in combination with propranolol;Experimental

Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol; or

GPC-100 in combination with propranolol and G-CSFExperimental

Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol and G-CSF.

Drugs: GPC-100, Propranolol, G-CSF

Sites

10 sites in 1 country